 Emmaus Life Sciences Inc OTCQX:EMMA co-founder and CEO Dr Yutaka Niihara has told investors that the commercial-stage biopharmaceutical company successfully expanded market and patient access to sickle cell treatment Endari during the first quarter. Immediately after the United Arab Emirates, granted full marketing authorization in March, we received a significant order from one of our distributors in the country and expect to see a continuing flow of orders going forward, Dr Niihara said in an earnings statement. 